ESR1 and breast cancer: Our findings suggest that adjuvant endocrine therapy should be limited to hormone receptor-positive BC based on evidence demonstrating that additional hormone therapy is not beneficial in patients with the ER-negative/PR-negative subtype.30 However, the value of single hormone receptor–positivity for assessing the benefit from endocrine therapy remains unknown.